X Bioscience PCL (BKK:XBIO)
Thailand · Delayed Price · Currency is THB 0.0700
0.00 (0.00%)
At close: Sep 3, 2026
X Bioscience PCL Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 212.5 | 129.65 | 319.24 | 311.77 | 344.49 | 254.04 | |
Revenue Growth | -14.53% | -59.39% | 2.40% | -9.50% | 35.60% | -38.88% |
Cost of Revenue | 128.61 | 76.61 | 180.63 | 159.67 | 172.3 | 126.82 |
Gross Profit | 83.88 | 53.04 | 138.61 | 152.11 | 172.18 | 127.23 |
Selling, General & Admin | 832.1 | 507.35 | 389.82 | 272.53 | 455.41 | 227.79 |
Operating Expenses | 832.1 | 507.35 | 389.82 | 272.53 | 455.41 | 227.79 |
Operating Income | -748.21 | -454.31 | -251.21 | -120.43 | -283.23 | -100.56 |
Interest Expense | -21.37 | -26.22 | -34.29 | -39.94 | -56.52 | -14.45 |
Interest & Investment Income | - | - | - | - | - | 0.01 |
Other Non Operating Income (Expenses) | 12.03 | 6.26 | 7.58 | 11.72 | 3.33 | 9.45 |
EBT Excluding Unusual Items | -757.55 | -474.26 | -277.92 | -148.65 | -336.41 | -105.55 |
Impairment of Goodwill | -69.41 | - | - | - | - | - |
Gain (Loss) on Sale of Assets | 177.91 | 18.53 | - | - | - | - |
Asset Writedown | -67.42 | - | - | - | - | - |
Pretax Income | -716.48 | -455.74 | -277.92 | -148.65 | -336.41 | -105.55 |
Income Tax Expense | -13.86 | -3.25 | -15.84 | -1.13 | -5.65 | -5.65 |
Earnings From Continuing Operations | -702.62 | -452.49 | -262.07 | -147.52 | -330.77 | -99.9 |
Earnings From Discontinued Operations | -17.26 | -16.94 | - | - | -245.22 | -176.55 |
Net Income to Company | -719.88 | -469.43 | -262.07 | -147.52 | -575.99 | -276.45 |
Minority Interest in Earnings | 1.14 | 0.57 | 1.85 | - | - | - |
Net Income | -718.74 | -468.87 | -260.22 | -147.52 | -575.99 | -276.45 |
Net Income to Common | -718.74 | -468.87 | -260.22 | -147.52 | -575.99 | -276.45 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 3,597 | 402 | 184 | 125 | 116 | 116 |
Shares Outstanding (Diluted) | 3,597 | 402 | 184 | 125 | 116 | 116 |
Shares Change | 216.98% | 118.20% | 46.88% | 7.78% | - | 19.79% |
EPS (Basic) | -0.20 | -1.17 | -1.41 | -1.18 | -4.95 | -2.38 |
EPS (Diluted) | -0.20 | -1.17 | -1.41 | -1.18 | -4.95 | -2.38 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -352.01 | -78.88 | -54.84 | -133.59 | -291.22 | -212.57 |
Free Cash Flow Per Share | -0.10 | -0.20 | -0.30 | -1.07 | -2.50 | -1.83 |
Gross Margin | 39.48% | 40.91% | 43.42% | 48.79% | 49.98% | 50.08% |
Operating Margin | -352.11% | -350.40% | -78.69% | -38.63% | -82.22% | -39.58% |
Profit Margin | -338.24% | -361.63% | -81.51% | -47.32% | -167.20% | -108.82% |
Free Cash Flow Margin | -165.66% | -60.84% | -17.18% | -42.85% | -84.54% | -83.67% |
EBITDA | -733.73 | -436.4 | -224.53 | -102.69 | -189.44 | -13.51 |
EBITDA Margin | - | - | -70.33% | -32.94% | -54.99% | -5.32% |
D&A For EBITDA | 14.48 | 17.9 | 26.68 | 17.73 | 93.79 | 87.05 |
EBIT | -748.21 | -454.31 | -251.21 | -120.43 | -283.23 | -100.56 |
EBIT Margin | - | - | -78.69% | -38.63% | -82.22% | -39.58% |